NORTREL 7/7/7
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NORTREL 7/7/7 (NORTREL 7/7/7).
Combination estrogen-progestin oral contraceptive. Suppresses gonadotropin release, inhibiting ovulation. Increases cervical mucus viscosity and alters endometrial receptivity.
| Metabolism | Ethinyl estradiol: primarily metabolized by CYP3A4; undergoes first-pass metabolism. Norethindrone: metabolized by reduction and conjugation; primarily via CYP3A4. |
| Excretion | Renal excretion of metabolites (primarily ethinyl estradiol and norelgestromin conjugates) accounts for approximately 50% of elimination; fecal/biliary excretion accounts for the remainder (about 35-40% fecal, 10-15% biliary). |
| Half-life | Norelgestromin terminal half-life is approximately 28 hours; ethinyl estradiol terminal half-life is approximately 17 hours. The extended half-life supports once-weekly dosing. |
| Protein binding | Norelgestromin is 99% bound primarily to albumin and sex hormone-binding globulin; ethinyl estradiol is 98% bound primarily to albumin. |
| Volume of Distribution | Norelgestromin apparent Vd/F is approximately 2.1 L/kg; ethinyl estradiol apparent Vd/F is approximately 5.5 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Transdermal bioavailability of norelgestromin and ethinyl estradiol is approximately 60-65% relative to oral administration due to avoidance of first-pass metabolism. |
| Onset of Action | Clinical contraceptive effect is achieved within 7 days of initial application if started on the first day of menstruation; ovulation inhibition is established within the first week. |
| Duration of Action | Each transdermal patch provides contraceptive efficacy for 7 days; three consecutive weekly patches are used followed by a 7-day patch-free interval. |
One tablet orally once daily, taken at the same time each day. Each tablet contains norethindrone 0.5 mg/ethinyl estradiol 35 mcg for days 1-7, norethindrone 0.75 mg/ethinyl estradiol 35 mcg for days 8-14, and norethindrone 1 mg/ethinyl estradiol 35 mcg for days 15-21, followed by 7 placebo tablets.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment recommended for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure due to potential for decreased drug elimination and hormonal alterations. |
| Liver impairment | Contraindicated in acute hepatic disease or severe hepatic insufficiency (Child-Pugh class C). For Child-Pugh class A or B, use with caution; consider alternative contraception due to possible impaired hormone metabolism. No specific dose adjustment guidelines available. |
| Pediatric use | Safety and efficacy in postmenarchal pediatric patients have been established. Dose is the same as for adults: one tablet orally once daily following the 28-day regimen. |
| Geriatric use | Not indicated for use in postmenopausal women. No studies in geriatric population; use is not appropriate due to lack of need for contraception. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NORTREL 7/7/7 (NORTREL 7/7/7).
| Breastfeeding | Combined hormonal contraceptives may reduce milk production and pass into breast milk. The M/P ratio for ethinyl estradiol is approximately 0.3-0.5; for norethindrone, minimal transfer. Use is generally not recommended during breastfeeding, especially in the early postpartum period. Alternative contraception advised. |
| Teratogenic Risk | First trimester: No known association with major congenital anomalies based on population data. However, exposure to ethinyl estradiol and norethindrone acetate is not recommended during pregnancy due to theoretical risks from hormonal exposure. Second and third trimesters: Not indicated for use; hormonal contraceptives should be discontinued if pregnancy occurs. No evidence of fetal harm from inadvertent use early in pregnancy. |
■ FDA Black Box Warning
Cigarette smoking increases risk of serious cardiovascular events. Use is contraindicated in women over 35 who smoke.
| Serious Effects |
Thrombophlebitis, thromboembolic disorders, cerebral vascular disease, coronary artery disease, known or suspected pregnancy, undiagnosed abnormal genital bleeding, known or suspected breast cancer, liver tumor or active liver disease, hypersensitivity to components, and women over 35 who smoke.
| Precautions | Increased risk of thromboembolic disorders, myocardial infarction, stroke, hepatic neoplasia, gallbladder disease. Discontinue if jaundice, visual disturbances, or migraine occurs. Blood pressure should be monitored. |
Loading safety data…
| Fetal Monitoring | Pregnancy test before initiation and if pregnancy suspected. Monitor for signs of thrombotic events (e.g., DVT, PE) and hypertension. No specific fetal monitoring required unless exposure occurs during pregnancy. |
| Fertility Effects | Suppresses ovulation via combined hormonal activity. No permanent impairment of fertility; normal fertility returns upon discontinuation. No evidence of long-term adverse effects on oocyte or sperm quality. |